Β-Thalassemia Treatment with KL003 Cell Injection

Kanglin Biotechnology (Hangzhou) Co., Ltd.

Status and phase

Enrolling

Phase 2

Phase 1

Conditions

Transfusion-dependent Beta-Thalassemia

Treatments

Drug: KL003 Cell Injection Drug Product

Study type

Interventional

Funder types

Industry

Identifiers

NCT06280378

CP-KL003-003/01

Details and patient eligibility

About

This is a non-randomized, open label, single-dose study in up to 41 participants with β-thalassemia major. The goal of this clinical trial is to evaluate the safety and efficacy of KL003 cell injection in subjects with β-thalassemia major.

Full description

This is a single-arm, multi-site, single-dose, Phase 1/2 study to assess KL003 Cell Injection in up to 41 participants with transfusion-dependent β-thalassemia (TDT) who are ≥3 and ≤35 years of age. KL003 Cell Injection is autologous CD34+ stem cells transduced Ex Vivo with a lentiviral Vector encoding βA-T87Q-Globin.

Enrollment

41 estimated patients

Sex

All

Ages

3 to 35 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female age between 3-35 years;
Diagnosis of transfusion-dependent β-thalassemia and a history of at least 100 mL/kg/year of pRBCs or ≥8 transfusions of pRBCs per year for the prior 2 years;
Karnofsky performance status ≥70 for participants≥16 years of age; Lansky performance status of ≥70 for participants<16 years of age;
Eligible to undergo auto-HSCT;
Willing and able to follow the research procedures and conditions, with good compliance;
Willing to receive at least the 2 years follow-up;
Participant and/or legal guardians voluntarily participated in this clinical trial and signed the informed consent form.

Exclusion criteria

Diagnosis of composite α thalassemia;
Prior receipt of gene therapy or allo-HSCT;
Meet the criteria for allo-HSCT and with an identified willing donor with full HLA match;
Participants with severe iron overload at the time of screening;
Presence of unusual antibody of red blood cell antigens or tested positive for platelet antibody;
Known allergy to clinical trial drug (plerixafor or G-CSF or busulfan) or ingredient(DMSO etc.);
Clinically significant and active bacterial, viral, fungal, or parasitic infection as determined by the clinical investigator;
Subjects positive with the following etiological tests: human immunodeficiency virus(HIV-1-2),human cytomegalovirus (HCMV-DNA),EB virus（EBV-DNA）,HBV (HBsAg/HBV-DNA positive),HCV antibody (HCV-Ab), Human T-lymphotropic virus antibody (HTLV-Ab), Treponema pallidum antibody (TP-Ab);
Uncorrectable coagulation dysfunction or history of severe bleeding disorder;
History of major organ damage including:
1. Liver function test suggest AST or ALT levels >3× upper limit of normal（ULN）;
2. Total serum bilirubin value>2.5×ULN;if combined with Gilbert syndrome, total bilirubin>3×ULN and direct bilirubin value>2.5×ULN;
3. Left ventricular ejection fraction <45%;
4. Baseline calculated eGFR<60mL/min/1.73m2;
5. Pulmonary function:FEV1/FVC<60% and/or diffusion capacity of carbon monoxide (DLco) <60% of prediction;